Kate Broderick, PhD, Chief Scientific and Innovation Officer at Artis BioSolutions, joined a TechCon panel on what the next era of medicine will require. The conversation ranged across pandemic learnings, regulatory modernization, and what AI is doing to development timelines. But the point she returned to was narrower and more structural than any of them.
Readiness is not something you can assemble when you need it.
The instinct after a crisis is to write a plan. Plans are useful. They are also not the constraint. When a novel pathogen emerges, or a program suddenly needs to move from bench to clinic in months rather than years, the binding limit is not whether someone documented what to do. It is whether the physical capability already exists and is already running: the suites, the qualified processes, the trained operators, the validated analytical methods, the raw material supply.
That distinction matters because standing capability cannot be built under pressure. A facility takes years. A quality system takes years. Trained manufacturing teams take longer than most program timelines allow. Capacity that only exists on paper, or that is mothballed between crises, is capacity that will not be there when the timeline compresses.
This is the argument for onshoring and for distributed manufacturing capability, and it is a more demanding argument than it first appears. Building domestic capacity is not the same as maintaining it. Infrastructure that sits idle degrades. People leave, equipment falls out of qualification, supplier relationships lapse. Readiness that is real is readiness that is in continuous use.
The clearest illustration is one the field lived through and has already started to forget.
During COVID, programs with fully designed constructs and validated science sat waiting on plasmid DNA. Turnaround times in the nine to twelve month range were not unusual. That was not a scientific delay. The biology was ready. The delay came from a starting material produced by bacterial fermentation, in a supply chain nobody in the program controlled, at a moment when every other program in the world was queued for the same capacity.
A year of waiting on a starting material is a full year of patients not treated. And the lesson is not specific to pandemics. It repeats, quietly and at smaller scale, in every advanced therapy program that discovers at tech transfer that its raw material supply was never a solved problem.
Here is where manufacturing readiness stops being a virtue and becomes an architecture question.
Most advanced therapy programs are assembled from vendors. One organization supplies the DNA. Another produces the vector or the drug substance. A third handles formulation and fill/finish. A fourth runs release testing. Each may be individually excellent. But the program's timeline is the sum of four queues, four quality systems, four sets of priorities, and three or four technology transfers, and every transfer is a point where methods drift, context is lost, and comparability risk enters the regulatory package.
Under normal conditions, that model is inefficient. Under pressure, it fails in a specific and predictable way: four vendors discover they have four different definitions of urgent, and none of them is yours.
Removing a handoff removes a queue, a transfer, and a failure mode at once. That is the whole case for integration, and it is why readiness is ultimately a structural property rather than an operational one. You cannot instrument your way to it after the fact.
Artis BioSolutions is built around that conclusion. The platform runs from foundational genetic material through GMP drug product, across US and EU sites, under one organization.
Synthetic DNA as the starting point. Our Bilbao facility produces GMP-ready synthetic linear DNA through a proprietary cell-free enzymatic platform, with no bacterial fermentation, no antibiotic resistance markers, no endotoxin burden, and sequence-agnostic production. GMP-ready starting material is available in as little as two weeks rather than months. The 37,000 sq ft site operates four cGMP processing suites, a fill/finish suite, and eight preclinical and R&D labs, with gram-scale production capacity.
Genetic medicines drug substance and drug product. Our Genetic Medicines Center of Excellence brings mRNA and LNP manufacturing in-house, which means a program can move from synthetic DNA through mRNA drug substance, LNP formulation, and GMP drug product without an external transfer.
Cell and gene therapy GMP manufacturing. Our Watertown, Massachusetts facility is 44,000 sq ft, purpose-built and reviewed with the FDA prior to construction, and houses 14,000 sq ft of GMP cleanroom across nine suites (eight ISO 7, one ISO 8). Cell processing suites for CAR-T, CAR-NK, and iPSC-derived products. Viral vector suites with processing up to 200L in stirred-tank bioreactors. An mRNA and LNP suite. Isolator-based fill/finish with closed robotic vial filling. In-house bioanalytical and microbiology QC, so the team that develops your analytical methods is the team that runs your release testing.
Development and GMP under the same roof and the same quality system. Process development, analytical development, and GMP manufacturing operate as one team rather than as sequential handoffs. The scientists who design a process are the scientists who see it through to GMP scale.
None of that is elegant for its own sake. It exists because the alternative is discovering, at the moment a program cannot afford it, that the capability you needed was distributed across four organizations with four different priorities.
The pandemic framing is useful because it makes the stakes legible. But the argument does not depend on the next outbreak.
Every advanced therapy program is already running the compressed-timeline experiment. A personalized cancer vaccine built from a patient's own tumor biopsy has a delivery window measured in weeks. An autologous CAR-T patient has a clinical status that does not pause for a manufacturing slot. A first-in-human study has a competitive landscape that moves whether or not your starting material arrives.
For those programs, manufacturing readiness is not insurance. It is the difference between a therapy that reaches patients inside the window that makes it work and one that does not.
That is what a competitive advantage in this field actually looks like. Not a faster process, but a shorter path with fewer places to stop.
Watch the full panel: Engineering the Next Era of Medicine, TechCon
Talk to us. If you are scoping a program and want to understand what an integrated path from synthetic DNA through GMP would mean for your timeline, we would like that conversation.